Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, Inc. (Nasdaq: AMRS) announced on March 1, 2021, its agreement to acquire Costa Brazil, a clean luxury beauty brand co-founded by Francisco Costa. This acquisition aims to enhance Amyris's position in the clean beauty sector, expanding its portfolio alongside brands like Biossance and Pipette. Costa Brazil’s products, driven by sustainable ingredients from the Amazon, align with Amyris’s commitment to social responsibility and clean formulation. Francisco Costa will join as Chief Creative Officer, expected to bring his expertise to further the company's growth in this booming market.
Amyris, Inc. (Nasdaq: AMRS) announced its participation in two upcoming investor conferences. These events include the Cowen 41st Annual Health Care Conference on March 4 at 12:10 PM ET and the H.C. Wainwright Global Life Sciences Conference on March 9 at 1:30 PM ET. Webcasts of the presentations will be available on the company's Investor Relations website. Amyris is known for its sustainable ingredients in the Clean Health and Beauty markets, reaching over 200 million consumers through its popular brands.
Amyris, Inc. (Nasdaq: AMRS) announced that its Pipette clean baby care brand will expand to over 600 Target stores across North America starting in March 2021. Since its 2019 launch, Pipette has seen significant growth, particularly among Millennial parents, with year-to-date retail sales trending over 8 times higher than the same period in 2020. Pipette products are known for being 100% nontoxic and EWG verified. This retail expansion builds on existing e-commerce momentum and solidifies Pipette's position in the sustainable personal care market.
Amyris announced promising preliminary data on its RNA COVID-19 vaccine platform, developed in collaboration with IDRI. This technology shows significant antibody production against the COVID-19 spike protein and is set to enter phase 1 clinical trials. The platform could address manufacturing and distribution challenges, including storage at refrigerator and room temperatures, improving accessibility in low-resource areas. Amyris is pursuing U.S. government funding to scale production and enhance its sustainable ingredient offerings.
Amyris, Inc. (Nasdaq: AMRS) will report its fourth quarter and full year 2020 financial results on March 2, 2021, before market opening. The release will be followed by a conference call at 6:00 am PT. CEO John Melo, CFO Han Kieftenbeld, and COO Eduardo Alvarez will discuss the financial results and business updates. Amyris focuses on sustainable ingredients for Clean Health and Beauty markets and owns three consumer brands: Biossance, Pipette, and Purecane. More information can be found on their website.
Amyris, Inc. (Nasdaq: AMRS) successfully conducted its second webinar in the virtual investor mini-series themed "Delivering on the Promise of Synthetic Biology" on February 9, 2021. The event attracted over 600 attendees, featuring insights from key executives including CEO John Melo and CFO Han Kieftenbeld. Highlights included updates on strategic transactions, the beauty market, and planned product launches in 2021, with a focus on expansion in China. A replay of the webinar is available on Amyris's investor relations website.
Amyris, a leader in synthetic biotechnology, announced its second webinar in the virtual investor mini-series titled "Delivering on the Promise of Synthetic Biology". Scheduled for February 9, 2021, at 1:00 PM ET, this session focuses on The Science Delivering Clean and Sustainable Consumer Products, featuring a business update and Q&A. This format allows for targeted engagement on specific investor topics, with a third session following later in Q2 2021. The live event can be accessed via Amyris's investor relations site.
Amyris, Inc. (Nasdaq: AMRS) announced significant results from an early clinical study of its clean topical acne formulation made from fermentation-based ingredients. Conducted by Princeton Consumer Research, the study showed Amyris's formulation performed better than 10 standard acne treatments in terms of efficacy and speed of acne reduction. The global acne treatment market is valued at $11 billion, with increasing demand due to conditions like 'maskne'. Amyris aims to finalize this formulation for consumer launch, potentially positioning itself as a leader in the clean beauty market.
Amyris, Inc. (Nasdaq: AMRS) announced on January 22, 2021, the launch of its Terasana brand, which will offer clean beauty products made from sustainably sourced natural cannabinoids. This move expands Amyris's clean beauty portfolio beyond existing brands like Biossance and Pipette. The company leverages its proprietary Lab-to-Market synthetic biology platform to create effective skincare solutions using CBG (cannabigerol) derived from sugarcane. Early clinical results indicate that these CBG formulations outperform standard CBD products for various skin conditions, positioning Amyris favorably in the cannabinoid market.
Amyris, Inc. (Nasdaq: AMRS) has been recognized as one of the top global organizations for social and environmental impact, ranked #23 out of 150 by Real Leaders in their 2021 Impact Awards. This achievement is attributed to Amyris's rapid revenue growth, which doubled from 2017 to 2019, showcasing its potential in sustainable products. The company is expanding its consumer brands, including new haircare offerings and entering the Greater China market. The awards ceremony will take place on January 27, 2021.
